These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 22500688)

  • 1. Targeting the Met pathway in lung cancer.
    Belalcazar A; Azaña D; Perez CA; Raez LE; Santos ES
    Expert Rev Anticancer Ther; 2012 Apr; 12(4):519-28. PubMed ID: 22500688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
    Puri N; Khramtsov A; Ahmed S; Nallasura V; Hetzel JT; Jagadeeswaran R; Karczmar G; Salgia R
    Cancer Res; 2007 Apr; 67(8):3529-34. PubMed ID: 17440059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of EGFR inhibition in the treatment of non-small cell lung cancer.
    Ray M; Salgia R; Vokes EE
    Oncologist; 2009 Nov; 14(11):1116-30. PubMed ID: 19892771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
    Ma PC; Schaefer E; Christensen JG; Salgia R
    Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy.
    Stabile LP; Lyker JS; Huang L; Siegfried JM
    Gene Ther; 2004 Feb; 11(3):325-35. PubMed ID: 14737093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A simple view on lung cancer biology: the MET pathway].
    Ruppert AM; Beau-Faller M; Belmont L; Lavolé A; Gounant V; Cadranel J; Wislez M
    Rev Mal Respir; 2011 Dec; 28(10):1241-9. PubMed ID: 22152933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer.
    Ettinger DS
    Oncologist; 2006 Apr; 11(4):358-73. PubMed ID: 16614231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
    Bunn PA; Thatcher N
    Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer.
    Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Faus-Dáder MJ; Calleja-Hernández MÁ
    Pharmacol Res; 2015 Dec; 102():90-106. PubMed ID: 26413995
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
    Sadiq AA; Geynisman DM; Salgia R
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1810-1. PubMed ID: 22005540
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting FGFR, ephrins, Mer, MET, and PDGFR-α in non-small cell lung cancer.
    Riess JW; Neal JW
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1797-8. PubMed ID: 22005534
    [No Abstract]   [Full Text] [Related]  

  • 13. MET signaling: novel targeted inhibition and its clinical development in lung cancer.
    Feng Y; Thiagarajan PS; Ma PC
    J Thorac Oncol; 2012 Feb; 7(2):459-67. PubMed ID: 22237263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of c-MET pathway inhibitors.
    Liu X; Newton RC; Scherle PA
    Expert Opin Investig Drugs; 2011 Sep; 20(9):1225-41. PubMed ID: 21740293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET...
    Scagliotti GV; Di Maio M
    Ann Oncol; 2015 Oct; 26(10):2007-9. PubMed ID: 26265168
    [No Abstract]   [Full Text] [Related]  

  • 16. Emerging science and therapies in non-small-cell lung cancer: targeting the MET pathway.
    Kris MG; Arenberg DA; Herbst RS; Riely GJ
    Clin Lung Cancer; 2014 Nov; 15(6):475. PubMed ID: 25306384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic biomarkers: falling short of the mark?
    Gainor JF; Longo DL; Chabner BA
    Clin Cancer Res; 2014 May; 20(10):2587-94. PubMed ID: 24831281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of MetMAb (OA-5D5) in c-MET active lung malignancies.
    Surati M; Patel P; Peterson A; Salgia R
    Expert Opin Biol Ther; 2011 Dec; 11(12):1655-62. PubMed ID: 22047509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new drugs and biologics as sensitizers in the treatment of non-small cell lung cancer.
    Turrisi AT
    Suppl Tumori; 2002; 1(4):S55-7. PubMed ID: 12415822
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of receptor tyrosine kinases in lung cancer.
    Maulik G; Kijima T; Salgia R
    Methods Mol Med; 2003; 74():113-25. PubMed ID: 12415690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.